Although these effects may be apparently lost immediately after discontinuation of the GLP-1RA therapy, there seems to be a long-term imprint effect on the first-phase insulin secretion, which is worth pursuing in all patients with T2DM who can tolerate, and are good candidates for, GLP-1RA therapy. Here, INS is linked to type 2 diabetes mellitus.